Chemoradiation with paclitaxel and radiotherapy resulted in complete metabolic response of primary seminal vesicle angiosarcoma lesion and affected lymph node at 2 months post-treatment in a 52-year-old male patient.
Case Report (n=1)
No
Definitive chemoradiation achieved an early complete metabolic response in a rare case of primary seminal vesicle angiosarcoma, suggesting a potential alternative approach for inoperable disease.
Effect estimate: Complete metabolic response
Primary angiosarcoma of the seminal vesicle is an exceptionally rare genitourinary malignancy, with very few cases reported in the literature. Due to its rarity, nonspecific presentation, and lack of standardized treatment protocols, diagnosis and management remain challenging. This case adds to the limited body of evidence by describing clinical presentation, diagnostic workup, therapeutic approach, and early treatment response in one of the few documented cases worldwide. A 52-year-old male presented with persistent genitourinary symptoms and had been treated for three years as a case of chronic prostatitis without clinical improvement. Further evaluation revealed findings suspicious for a malignant seminal vesicle lesion. Comprehensive diagnostic assessment, including imaging and histopathological evaluation, confirmed primary angiosarcoma of the seminal vesicle. The patient underwent multimodal therapy consisting of chemotherapy and radiotherapy. Post-treatment evaluation demonstrated an early complete metabolic response on imaging studies. However, follow-up duration was limited to two months following completion of therapy. Primary angiosarcoma of the seminal vesicle is a rare and diagnostically challenging tumor that may mimic benign urological conditions, potentially delaying diagnosis. Multimodal treatment involving chemoradiation may provide early therapeutic response, particularly in patients with inoperable disease. Nevertheless, longer follow-up is essential given the aggressive nature and high recurrence risk associated with angiosarcoma. Further molecular and genetic research is required to identify targeted treatment strategies for this rare malignancy.
Albayeh et al. (Sat,) conducted a case report in Primary angiosarcoma of the seminal vesicle (n=1). Chemoradiation (Paclitaxel chemotherapy and localized radiation therapy) vs. No surgery or other treatment was evaluated on Complete metabolic response on post-treatment PET/CT imaging at 2 months post therapy (Complete metabolic response). Chemoradiation with paclitaxel and radiotherapy resulted in complete metabolic response of primary seminal vesicle angiosarcoma lesion and affected lymph node at 2 months post-treatment in a 52-year-old male patient.